The use of diuretics to increase radioiodine (RAI) uptake in patients with differentiated thyroid cancer

被引：0
|
作者：
Orquiza, Michael [1 ]
Van Nostrand, Douglas [1 ]
机构：
[1] MedStar Wash Hosp Ctr, Div Nucl Med, Washington, DC USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 2014年 / 55卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
1367
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients
    Verburg, FA
    de Keizer, B
    Lips, CJM
    Zelissen, PMJ
    de Klerk, JMH
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2005, 152 (01) : 33 - 37
  • [42] Respiratory distress caused by radioiodine therapy in patients with differentiated thyroid cancer
    Seigo Kinuya
    Kunihiko Yokoyama
    Takatoshi Michigishi
    Norihisa Tonami
    Annals of Nuclear Medicine, 2006, 20
  • [43] The efficacy of low dose radioiodine therapy in differentiated thyroid cancer patients
    Yoon, S.
    Choi, B.
    Hong, S.
    Joh, C.
    Yoon, J.
    Lee, K.
    So, E.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S374 - S374
  • [44] INFLUENCE OF HYDROCHLOROTHIAZIDE ON URINARY EXCRETION OF RADIOIODINE IN PATIENTS WITH DIFFERENTIATED THYROID CANCER
    Ignjatovic, V. D.
    Vukomanovic, V.
    Jeremic, M.
    Ignjatovic, V. S.
    Matovic, M.
    ACTA ENDOCRINOLOGICA-BUCHAREST, 2015, 11 (03) : 396 - 400
  • [45] Impact of age on survival in radioiodine refractory differentiated thyroid cancer patients
    Saie, C.
    Wassermann, J.
    Mathy, E.
    Chereau, N.
    Leenhardt, L.
    du Montcel, S. Tezenas
    Buffet, C.
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2021, 184 (05) : 667 - 676
  • [46] Is denying RAI ablation in the low risk differentiated thyroid cancer patients justified?
    Agrawal, K.
    Kashyap, R.
    Bhattacharya, A.
    Mittal, B. R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S223 - S224
  • [47] Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma
    Hoftijzer, Hendrieke
    Heemstra, Karen A.
    Morreau, Hans
    Stokkel, Marcel P.
    Corssmit, Eleonora P.
    Gelderblom, Hans
    Weijers, Karin
    Pereira, Alberto M.
    Huijberts, Maya
    Kapiteijn, Ellen
    Romijn, Johannes A.
    Smit, Johannes W.
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2009, 161 (06) : 923 - 931
  • [48] Radioiodine uptake by thyroglossal duct remnant after radioiodine therapy for differentiated thyroid carcinoma
    Jinguji, M.
    Nakajo, M.
    Tani, A.
    Yoshiura, T.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S783 - S784
  • [49] THYROID SUPPRESSION AND RADIOIODINE TREATMENT FOR DIFFERENTIATED THYROID-CANCER
    ROSLER, H
    ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 1987, 113 (07) : 778 - 778
  • [50] Analysis of tumor growth rate for radioiodine (RAI)-refractory differentiated thyroid cancer patients receiving placebo and/or sorafenib in the phase III DECISION study
    Fassnacht, M.
    Kappeler, C.
    Healy, D. P.
    Baumer, C.
    Meinhardt, G.
    Elisei, R.
    Schlumberger, M.
    Brose, M. S.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 9 - 9
12345